Relationship between SRD5A2 rs9282858 polymorphism and the susceptibility of prostate cancer

Abstract

The pathogenetic mechanism of prostate cancer (PCA) has not been understood completely, and gene polymorphisms have been demonstrated to play a critical role in the course. It has been reported that rs9282858 polymorphism of steroid 5--reductase type 2 (SRD5A2) may affect the susceptibility of PCA, but some researches showed different results. We therefore carried out a meta-analysis to clarify this relationship. Relevant studies were identified through PubMed and Chinese National Knowledge Infrastructure databases concerning the association between SRD5A2 rs9282858 polymorphism and PCA. Odds ratios (ORs) with their 95% confidence intervals (95% CIs) were calculated to assess the strength of the association. Additionally, stratified analyses were performed based on ethnicity and source of control. Besides, heterogeneity test, sensitivity analysis, and publication bias evaluation were conducted in current meta-analysis as well. Ultimately, 20 publications incorporating 30 case-control studies were included in this meta-analysis, involving a total of 7300 cases and 7952 controls. The overall results demonstrated that SRD5A2 rs9282858 polymorphism was remarkably associated with increased susceptibility of PCA (TT vs. AA: OR=4.08, 95% CI=1.94-8.58; TT+AT vs. AA: OR=1.28, 95% CI=1.11-1.47; TT vs. AA+AT: OR=4.44, 95% CI=2.12-9.27; allele T vs. allele A: OR=1.34, 95% CI=1.17-1.54). After subgroup analyses by ethnicity and source of control, we also observed a similar trend in Latinos, other-ethnicity, population-based, and hospital-based groups under corresponding genetic models. Our findings indicate that SRD5A2 rs9282858 polymorphism may be a susceptible factor to PCA.